Pharmacologic medical therapies for hypoparathyroidism include calcium and Vitamin D3 supplementation. Severe hypocalcemia, a potentially life-threatening condition,  is treated as soon as possible with intravenous calcium (e.g. as calcium gluconate). Generally, a central venous catheter is recommended, as the calcium can irritate peripheral veins and cause phlebitis. Natpara (rhPTH) is a synthetic recombinant human parathyroid hormone approved by U.S. FDA in 2015 for treatment of hypoparathyroidism.
Hypoparathyroidism medical therapy
Pseudohypoparathyroidism medical therapy
Hyperparathyroidism medical therapy
Hypoparathyroidism future or investigational therapies
Vitamin D deficiency medical therapy
Pseudohypoparathyroidism primary prevention
Hypoparathyroidism primary prevention
Pseudohypoparathyroidism secondary prevention